Despite the efficacy of targeted therapy using TKI for patients with activating driver mutation (two major types: Del19 and L858R) on EGFR, management of these patients who eventually develop resistance to EGFR-TKI has become the biggest challenge in lung cancer therapy and remains unmet clinical need10,34,35. Here, EGFR is linked to lung carcinoma.